Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
41
INFIQ Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
1.36%
Day range:
$0.0001 - $0.0001
52-week range:
$0.0000 - $0.0026
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
--
Volume:
1.6K
Avg. volume:
9.1K
1-year change:
--
Market cap:
$100
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INFIQ
Infinity Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
ATHXQ
Athersys, Inc.
|
-- | -- | -- | -- | -- |
|
BSSP
Bassline Productions, Inc.
|
-- | -- | -- | -- | -- |
|
ELOX
Eloxx Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
MRZM
Marizyme, Inc.
|
-- | -- | -- | -- | -- |
|
SEELQ
Seelos Therapeutics, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INFIQ
Infinity Pharmaceuticals, Inc.
|
$0.0000 | -- | $100 | -- | $0.00 | 0% | 0.00x |
|
ATHXQ
Athersys, Inc.
|
$0.0000 | -- | $100 | -- | $0.00 | 0% | 0.00x |
|
BSSP
Bassline Productions, Inc.
|
$0.0000 | -- | $400 | -- | $0.00 | 0% | -- |
|
ELOX
Eloxx Pharmaceuticals, Inc.
|
$0.0001 | -- | $300 | -- | $0.00 | 0% | 0.00x |
|
MRZM
Marizyme, Inc.
|
$0.0000 | -- | $100 | -- | $0.00 | 0% | 0.00x |
|
SEELQ
Seelos Therapeutics, Inc.
|
$0.0000 | -- | -- | -- | $0.00 | 0% | 0.00x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INFIQ
Infinity Pharmaceuticals, Inc.
|
-- | 67.071 | -- | -- |
|
ATHXQ
Athersys, Inc.
|
-- | 401.232 | -- | -- |
|
BSSP
Bassline Productions, Inc.
|
-- | 0.000 | -- | -- |
|
ELOX
Eloxx Pharmaceuticals, Inc.
|
-- | -351.174 | -- | -- |
|
MRZM
Marizyme, Inc.
|
192.4% | 14.269 | 193.54% | 0.00x |
|
SEELQ
Seelos Therapeutics, Inc.
|
-- | 170.665 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INFIQ
Infinity Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- | -- |
|
ATHXQ
Athersys, Inc.
|
-- | -- | -- | -- | -- | -- |
|
BSSP
Bassline Productions, Inc.
|
-- | -- | -- | -- | -- | -- |
|
ELOX
Eloxx Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- | -- |
|
MRZM
Marizyme, Inc.
|
-- | -$1.6M | -529.96% | -- | -6283.56% | -$732.9K |
|
SEELQ
Seelos Therapeutics, Inc.
|
-- | -- | -- | -- | -- | -- |
Infinity Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns INFIQ or ATHXQ?
Athersys, Inc. has a net margin of -- compared to Infinity Pharmaceuticals, Inc.'s net margin of --. Infinity Pharmaceuticals, Inc.'s return on equity of -- beat Athersys, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INFIQInfinity Pharmaceuticals, Inc.-- -- -- ATHXQAthersys, Inc.-- -- -- -
What do Analysts Say About INFIQ or ATHXQ?
Infinity Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 29999900%. On the other hand Athersys, Inc. has an analysts' consensus of -- which suggests that it could grow by 549999900%. Given that Athersys, Inc. has higher upside potential than Infinity Pharmaceuticals, Inc., analysts believe Athersys, Inc. is more attractive than Infinity Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFIQInfinity Pharmaceuticals, Inc.0 0 0 ATHXQAthersys, Inc.0 0 0 -
Is INFIQ or ATHXQ More Risky?
Infinity Pharmaceuticals, Inc. has a beta of 6.447, which suggesting that the stock is 544.677% more volatile than S&P 500. In comparison Athersys, Inc. has a beta of 50.384, suggesting its more volatile than the S&P 500 by 4938.411%.
-
Which is a Better Dividend Stock INFIQ or ATHXQ?
Infinity Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Athersys, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Infinity Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Athersys, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFIQ or ATHXQ?
Infinity Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Athersys, Inc. quarterly revenues of --. Infinity Pharmaceuticals, Inc.'s net income of -- is lower than Athersys, Inc.'s net income of --. Notably, Infinity Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Athersys, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Infinity Pharmaceuticals, Inc. is 0.00x versus 0.00x for Athersys, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFIQInfinity Pharmaceuticals, Inc.0.00x -- -- -- ATHXQAthersys, Inc.0.00x -- -- --
-
Which has Higher Returns INFIQ or BSSP?
Bassline Productions, Inc. has a net margin of -- compared to Infinity Pharmaceuticals, Inc.'s net margin of --. Infinity Pharmaceuticals, Inc.'s return on equity of -- beat Bassline Productions, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INFIQInfinity Pharmaceuticals, Inc.-- -- -- BSSPBassline Productions, Inc.-- -- -- -
What do Analysts Say About INFIQ or BSSP?
Infinity Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 29999900%. On the other hand Bassline Productions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Infinity Pharmaceuticals, Inc. has higher upside potential than Bassline Productions, Inc., analysts believe Infinity Pharmaceuticals, Inc. is more attractive than Bassline Productions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFIQInfinity Pharmaceuticals, Inc.0 0 0 BSSPBassline Productions, Inc.0 0 0 -
Is INFIQ or BSSP More Risky?
Infinity Pharmaceuticals, Inc. has a beta of 6.447, which suggesting that the stock is 544.677% more volatile than S&P 500. In comparison Bassline Productions, Inc. has a beta of 84.573, suggesting its more volatile than the S&P 500 by 8357.261%.
-
Which is a Better Dividend Stock INFIQ or BSSP?
Infinity Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bassline Productions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Infinity Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Bassline Productions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFIQ or BSSP?
Infinity Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Bassline Productions, Inc. quarterly revenues of --. Infinity Pharmaceuticals, Inc.'s net income of -- is lower than Bassline Productions, Inc.'s net income of --. Notably, Infinity Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Bassline Productions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Infinity Pharmaceuticals, Inc. is 0.00x versus -- for Bassline Productions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFIQInfinity Pharmaceuticals, Inc.0.00x -- -- -- BSSPBassline Productions, Inc.-- -- -- --
-
Which has Higher Returns INFIQ or ELOX?
Eloxx Pharmaceuticals, Inc. has a net margin of -- compared to Infinity Pharmaceuticals, Inc.'s net margin of --. Infinity Pharmaceuticals, Inc.'s return on equity of -- beat Eloxx Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INFIQInfinity Pharmaceuticals, Inc.-- -- -- ELOXEloxx Pharmaceuticals, Inc.-- -- -- -
What do Analysts Say About INFIQ or ELOX?
Infinity Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 29999900%. On the other hand Eloxx Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 29999900%. Given that Infinity Pharmaceuticals, Inc. has higher upside potential than Eloxx Pharmaceuticals, Inc., analysts believe Infinity Pharmaceuticals, Inc. is more attractive than Eloxx Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFIQInfinity Pharmaceuticals, Inc.0 0 0 ELOXEloxx Pharmaceuticals, Inc.0 0 0 -
Is INFIQ or ELOX More Risky?
Infinity Pharmaceuticals, Inc. has a beta of 6.447, which suggesting that the stock is 544.677% more volatile than S&P 500. In comparison Eloxx Pharmaceuticals, Inc. has a beta of -76.396, suggesting its less volatile than the S&P 500 by 7739.587%.
-
Which is a Better Dividend Stock INFIQ or ELOX?
Infinity Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eloxx Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Infinity Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eloxx Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFIQ or ELOX?
Infinity Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Eloxx Pharmaceuticals, Inc. quarterly revenues of --. Infinity Pharmaceuticals, Inc.'s net income of -- is lower than Eloxx Pharmaceuticals, Inc.'s net income of --. Notably, Infinity Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eloxx Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Infinity Pharmaceuticals, Inc. is 0.00x versus 0.00x for Eloxx Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFIQInfinity Pharmaceuticals, Inc.0.00x -- -- -- ELOXEloxx Pharmaceuticals, Inc.0.00x -- -- --
-
Which has Higher Returns INFIQ or MRZM?
Marizyme, Inc. has a net margin of -- compared to Infinity Pharmaceuticals, Inc.'s net margin of -18950.82%. Infinity Pharmaceuticals, Inc.'s return on equity of -- beat Marizyme, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INFIQInfinity Pharmaceuticals, Inc.-- -- -- MRZMMarizyme, Inc.70.64% -$0.03 $11.7M -
What do Analysts Say About INFIQ or MRZM?
Infinity Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 29999900%. On the other hand Marizyme, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Infinity Pharmaceuticals, Inc. has higher upside potential than Marizyme, Inc., analysts believe Infinity Pharmaceuticals, Inc. is more attractive than Marizyme, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFIQInfinity Pharmaceuticals, Inc.0 0 0 MRZMMarizyme, Inc.0 0 0 -
Is INFIQ or MRZM More Risky?
Infinity Pharmaceuticals, Inc. has a beta of 6.447, which suggesting that the stock is 544.677% more volatile than S&P 500. In comparison Marizyme, Inc. has a beta of 0.945, suggesting its less volatile than the S&P 500 by 5.509%.
-
Which is a Better Dividend Stock INFIQ or MRZM?
Infinity Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marizyme, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Infinity Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Marizyme, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFIQ or MRZM?
Infinity Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Marizyme, Inc. quarterly revenues of $32.9K. Infinity Pharmaceuticals, Inc.'s net income of -- is lower than Marizyme, Inc.'s net income of -$4.1M. Notably, Infinity Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Marizyme, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Infinity Pharmaceuticals, Inc. is 0.00x versus 0.00x for Marizyme, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFIQInfinity Pharmaceuticals, Inc.0.00x -- -- -- MRZMMarizyme, Inc.0.00x -- $32.9K -$4.1M
-
Which has Higher Returns INFIQ or SEELQ?
Seelos Therapeutics, Inc. has a net margin of -- compared to Infinity Pharmaceuticals, Inc.'s net margin of --. Infinity Pharmaceuticals, Inc.'s return on equity of -- beat Seelos Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INFIQInfinity Pharmaceuticals, Inc.-- -- -- SEELQSeelos Therapeutics, Inc.-- -- -- -
What do Analysts Say About INFIQ or SEELQ?
Infinity Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 29999900%. On the other hand Seelos Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 511999900%. Given that Seelos Therapeutics, Inc. has higher upside potential than Infinity Pharmaceuticals, Inc., analysts believe Seelos Therapeutics, Inc. is more attractive than Infinity Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFIQInfinity Pharmaceuticals, Inc.0 0 0 SEELQSeelos Therapeutics, Inc.0 0 0 -
Is INFIQ or SEELQ More Risky?
Infinity Pharmaceuticals, Inc. has a beta of 6.447, which suggesting that the stock is 544.677% more volatile than S&P 500. In comparison Seelos Therapeutics, Inc. has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.317%.
-
Which is a Better Dividend Stock INFIQ or SEELQ?
Infinity Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seelos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Infinity Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Seelos Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFIQ or SEELQ?
Infinity Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Seelos Therapeutics, Inc. quarterly revenues of --. Infinity Pharmaceuticals, Inc.'s net income of -- is lower than Seelos Therapeutics, Inc.'s net income of --. Notably, Infinity Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Seelos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Infinity Pharmaceuticals, Inc. is 0.00x versus 0.00x for Seelos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFIQInfinity Pharmaceuticals, Inc.0.00x -- -- -- SEELQSeelos Therapeutics, Inc.0.00x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
